{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:56:31Z","timestamp":1790142991474,"version":"4.0.1"},"reference-count":207,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2007,3,1]],"date-time":"2007-03-01T00:00:00Z","timestamp":1172707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2007,3]]},"DOI":"10.4065\/82.3.323","type":"journal-article","created":{"date-parts":[[2009,1,24]],"date-time":"2009-01-24T01:29:19Z","timestamp":1232760559000},"page":"323-341","source":"Crossref","is-referenced-by-count":26,"title":["Treatment of Newly Diagnosed Multiple Myeloma Based on Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART): Consensus Statement"],"prefix":"10.4065","volume":"82","author":[{"given":"Angela","family":"Dispenzieri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Vincent","family":"Rajkumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morie A.","family":"Gertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha Q.","family":"Lacy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Kyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip R.","family":"Greipp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas E.","family":"Witzig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Lust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne R.","family":"Hayman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaji","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven R.","family":"Zeldenrust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Leif","family":"Bergsagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig B.","family":"Reeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Keith","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Dalton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.4065\/82.3.323_bib1","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3322\/canjclin.56.2.106","article-title":"Cancer statistics, 2006","volume":"56","author":"Jemal","year":"2006","journal-title":"CA Cancer J Clin"},{"key":"10.4065\/82.3.323_bib2","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJM198302103080604","article-title":"Long-term survival in multiple myeloma","volume":"308","author":"Kyle","year":"1983","journal-title":"N Engl J Med"},{"key":"10.4065\/82.3.323_bib3","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1046\/j.1365-2141.1999.01462.x","article-title":"Long-term survival in multiple myeloma: a Finnish Leukaemia Group study","volume":"105","year":"1999","journal-title":"Br J Haematol"},{"key":"10.4065\/82.3.323_bib4","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","article-title":"A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival","volume":"36","author":"Durie","year":"1975","journal-title":"Cancer"},{"key":"10.4065\/82.3.323_bib5","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma [published correction appears in J Clin Oncol. 2005 Sep 1;23:6281]","volume":"23","author":"Greipp","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.4065\/82.3.323_bib6","doi-asserted-by":"crossref","DOI":"10.1038\/sj.leu.2404516","article-title":"A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy","author":"Stewart","year":"2007","journal-title":"Leukemia"},{"key":"10.4065\/82.3.323_bib7","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1182\/blood.V98.7.2229","article-title":"Hypodiploidy is a major prognostic factor in multiple myeloma","volume":"98","author":"Smadja","year":"2001","journal-title":"Blood"},{"key":"10.4065\/82.3.323_bib8","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1182\/blood-2002-10-3017","article-title":"Clinical and biologic implications of recurrent genomic aberrations in myeloma","volume":"101","author":"Fonseca","year":"2003","journal-title":"Blood"},{"key":"10.4065\/82.3.323_bib9","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1200\/JCO.2000.18.4.804","article-title":"Predictive role of interphase cytogenetics for survival of patients with multiple myeloma","volume":"18","author":"Konigsberg","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.4065\/82.3.323_bib10","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.1182\/blood.V86.11.4250.bloodjournal86114250","article-title":"Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities","volume":"86","author":"Tricot","year":"1995","journal-title":"Blood"},{"key":"10.4065\/82.3.323_bib11","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1182\/blood.V97.6.1566","article-title":"Chromosome 13 abnormalities identified by FISH analysis and serum b2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy","volume":"97","author":"Facon","year":"2001","journal-title":"Blood"},{"key":"10.4065\/82.3.323_bib12","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1046\/j.1365-2141.2002.03757.x","article-title":"Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma","volume":"118","author":"Fassas","year":"2002","journal-title":"Br J Haematol"},{"key":"10.4065\/82.3.323_bib13","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1038\/sj.leu.2404304","article-title":"Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma","volume":"20","author":"Chiecchio","year":"2006","journal-title":"Leukemia"},{"key":"10.4065\/82.3.323_bib14","doi-asserted-by":"crossref","first-page":"7296","DOI":"10.1200\/JCO.2005.01.3870","article-title":"Molecular classification of multiple myeloma: a distinct transcriptional profile characterizes patients expressing CCND1 and negative for 14q32 translocations","volume":"23","author":"Agnelli","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.4065\/82.3.323_bib15","doi-asserted-by":"crossref","first-page":"6333","DOI":"10.1200\/JCO.2005.05.021","article-title":"Molecular pathogenesis and a consequent classification of multiple myeloma","volume":"23","author":"Bergsagel","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.4065\/82.3.323_bib16","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1182\/blood-2005-11-013458","article-title":"The molecular classification of multiple myeloma","volume":"108","author":"Zhan","year":"2006","journal-title":"Blood"},{"key":"10.4065\/82.3.323_bib17","first-page":"733a","article-title":"A molecular classification of multiple myeloma (MM), based on cytogenetic abnormalities detected by interphase FISH, is powerful in identifying discrete groups of patients with dissimilar prognosis [abstract]","volume":"98","author":"Fonseca","year":"2001","journal-title":"Blood"},{"key":"10.4065\/82.3.323_bib18","doi-asserted-by":"crossref","first-page":"3915","DOI":"10.1182\/blood.V86.10.3915.bloodjournal86103915","article-title":"Interphase fluorescence in situ hybridization identifies chromosomal abnormalities in plasma cells from patients with monoclonal gammopathy of undetermined significance","volume":"86","author":"Drach","year":"1995","journal-title":"Blood"},{"key":"10.4065\/82.3.323_bib19","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1046\/j.1365-2141.1996.d01-2939.x","article-title":"Multiple myeloma: almost all patients are cytogenetically abnormal","volume":"94","author":"Zandecki","year":"1996","journal-title":"Br J Haematol"},{"key":"10.4065\/82.3.323_bib20","first-page":"1280","article-title":"Deletion of the retinoblastoma gene in multiple myeloma","volume":"8","author":"Dao","year":"1994","journal-title":"Leukemia"},{"key":"10.4065\/82.3.323_bib21","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1182\/blood.V66.2.380.380","article-title":"The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis","volume":"66","author":"Dewald","year":"1985","journal-title":"Blood"},{"key":"10.4065\/82.3.323_bib22","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0165-4608(94)00284-I","article-title":"Cytogenetic findings in 200 patients with multiple myeloma","volume":"82","author":"Sawyer","year":"1995","journal-title":"Cancer Genet Cytogenet"},{"key":"10.4065\/82.3.323_bib23","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1038\/sj.leu.2401041","article-title":"Chromosomal analysis in multiple myeloma: cytogenetic evidence of two different diseases","volume":"12","author":"Smadja","year":"1998","journal-title":"Leukemia"},{"key":"10.4065\/82.3.323_bib24","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/sj.bmt.1701943","article-title":"Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma","volume":"24","author":"Rajkumar","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"10.4065\/82.3.323_bib25","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0165-4608(99)00009-6","article-title":"Cytogenetic abnormalities correlate with the plasma cell labeling index and extent of bone marrow involvement in myeloma","volume":"113","author":"Rajkumar","year":"1999","journal-title":"Cancer Genet Cytogenet"},{"key":"10.4065\/82.3.323_bib26","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1182\/blood.V95.6.1925","article-title":"Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization","volume":"95","author":"Zojer","year":"2000","journal-title":"Blood"},{"key":"10.4065\/82.3.323_bib27","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1182\/blood.V66.2.338.338","article-title":"Prognostic implications of tumor cell DNA and RNA content in multiple myeloma","volume":"66","author":"Barlogie","year":"1985","journal-title":"Blood"},{"key":"10.4065\/82.3.323_bib28","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/ajh.2830300402","article-title":"Detection of hypodiploidy using multi-parameter flow cytometric analysis: a prognostic indicator in multiple myeloma","volume":"30","author":"Morgan","year":"1989","journal-title":"Am J Hematol"},{"key":"10.4065\/82.3.323_bib29","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/gcc.20375","article-title":"Analysis of genetic abnormalities provides insights into genetic evolution of hyperdiploid myeloma","volume":"45","author":"Chng","year":"2006","journal-title":"Genes Chromosomes Cancer"},{"key":"10.4065\/82.3.323_bib30","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood.V71.2.453.453","article-title":"Plasma cell karyotype in multiple myeloma","volume":"71","author":"Gould","year":"1988","journal-title":"Blood"},{"key":"10.4065\/82.3.323_bib31","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1046\/j.1365-2141.1998.00657.x","article-title":"Prognostic value of cytogenetics in multiple myeloma","volume":"101","author":"Seong","year":"1998","journal-title":"Br J Haematol"},{"key":"10.4065\/82.3.323_bib32","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/sj.leu.2402797","article-title":"Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma","volume":"17","author":"Debes-Marun","year":"2003","journal-title":"Leukemia"},{"key":"10.4065\/82.3.323_bib33","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1046\/j.1365-2141.2003.03948.x","article-title":"Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of total therapy II","volume":"120","author":"Shaughnessy","year":"2003","journal-title":"Br J Haematol"},{"key":"10.4065\/82.3.323_bib34","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1182\/blood-2003-02-0493","article-title":"The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma","volume":"102","author":"Fonseca","year":"2003","journal-title":"Blood"},{"key":"10.4065\/82.3.323_bib35","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1182\/blood.V93.3.1032","article-title":"Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics","volume":"93","author":"Garcia-Sanz","year":"1999","journal-title":"Blood"},{"key":"10.4065\/82.3.323_bib36","first-page":"3854","article-title":"Multiple myeloma: high incidence of chromosomal aneuploidy as detected by interphase fluorescence in situ hybridization","volume":"55","author":"Drach","year":"1995","journal-title":"Cancer Res"},{"key":"10.4065\/82.3.323_bib37","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1182\/blood.V91.9.3366","article-title":"Prognostic value of numerical chromosome aberrations in multiple myeloma: a FISH analysis of 15 different chromosomes","volume":"91","author":"Perez-Simon","year":"1998","journal-title":"Blood"},{"key":"10.4065\/82.3.323_bib38","first-page":"715","article-title":"Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: an Eastern Cooperative Oncology Group study","volume":"62","author":"Fonseca","year":"2002","journal-title":"Cancer Res"},{"key":"10.4065\/82.3.323_bib39","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/sj.leu.2404172","article-title":"Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations","volume":"20","author":"Chng","year":"2006","journal-title":"Leukemia"},{"key":"10.4065\/82.3.323_bib40","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1200\/JCO.1997.15.7.2659","article-title":"Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants","volume":"15","author":"Tricot","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.4065\/82.3.323_bib41","doi-asserted-by":"crossref","first-page":"4008","DOI":"10.1182\/blood.V95.12.4008","article-title":"Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities","volume":"95","author":"Desikan","year":"2000","journal-title":"Blood"},{"key":"10.4065\/82.3.323_bib42","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1182\/blood.V93.1.55","article-title":"Total therapy with tandem transplants for newly diagnosed multiple myeloma","volume":"93","author":"Barlogie","year":"1999","journal-title":"Blood"},{"key":"10.4065\/82.3.323_bib43","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/sj.leu.2402125","article-title":"Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy","volume":"15","author":"Fonseca","year":"2001","journal-title":"Leukemia"},{"key":"10.4065\/82.3.323_bib44","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s002770100296","article-title":"Deletion of chromosome 13q14 detected by fluorescence in situ hybridization has prognostic impact on survival after high-dose therapy in patients with multiple myeloma","volume":"80","author":"Worel","year":"2001","journal-title":"Ann Hematol"},{"issue":"suppl","key":"10.4065\/82.3.323_bib45","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1023\/A:1008300325610","article-title":"Recurrent immunoglobulin gene translocations identify distinct molecular subtypes of myeloma","volume":"11","author":"Chesi","year":"2000","journal-title":"Ann Oncol"},{"key":"10.4065\/82.3.323_bib46","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1182\/blood.V99.10.3735","article-title":"Myeloma and the t(11;14)(q13;q32): evidence for a biologically defined unique subset of patients","volume":"99","author":"Fonseca","year":"2002","journal-title":"Blood"},{"key":"10.4065\/82.3.323_bib47","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1182\/blood.V98.1.217","article-title":"Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma","volume":"98","author":"Shaughnessy","year":"2001","journal-title":"Blood"},{"key":"10.4065\/82.3.323_bib48","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/ng0797-260","article-title":"Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3","volume":"16","author":"Chesi","year":"1997","journal-title":"Nat Genet"},{"key":"10.4065\/82.3.323_bib49","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1182\/blood.V92.9.3025","article-title":"The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH\/MMSET hybrid transcripts","volume":"92","author":"Chesi","year":"1998","journal-title":"Blood"},{"key":"10.4065\/82.3.323_bib50","doi-asserted-by":"crossref","first-page":"4062","DOI":"10.1182\/blood.V90.10.4062","article-title":"A novel chromosomal translocation t(4; 14)(p16.3;q32) in multiple myeloma involves the fibroblast growth-factor receptor 3 gene","volume":"90","author":"Richelda","year":"1997","journal-title":"Blood"},{"key":"10.4065\/82.3.323_bib51","first-page":"5640","article-title":"High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies","volume":"58","author":"Avet-Loiseau","year":"1998","journal-title":"Cancer Res"},{"key":"10.4065\/82.3.323_bib52","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1054\/blre.2001.0154","article-title":"Laboratory correlates in multiple myeloma: how useful for prognosis?","volume":"15","author":"Fonseca","year":"2001","journal-title":"Blood Rev"},{"key":"10.4065\/82.3.323_bib53","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1046\/j.1365-2141.1999.01615.x","article-title":"P53 deletion is not a frequent event in multiple myeloma","volume":"106","author":"Avet-Loiseau","year":"1999","journal-title":"Br J Haematol"},{"key":"10.4065\/82.3.323_bib54","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1182\/blood.V92.3.802","article-title":"Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy","volume":"92","author":"Drach","year":"1998","journal-title":"Blood"},{"key":"10.4065\/82.3.323_bib55","first-page":"2539","article-title":"p53 and RAS gene mutations in multiple myeloma","volume":"7","author":"Portier","year":"1992","journal-title":"Oncogene"},{"key":"10.4065\/82.3.323_bib56","first-page":"758","article-title":"Inactivation of tumor suppressor genes, p53 and Rb1, in plasma cell dyscrasias","volume":"8","author":"Corradini","year":"1994","journal-title":"Leukemia"},{"key":"10.4065\/82.3.323_bib57","first-page":"1015","article-title":"Mutations of the p53 gene in human myeloma cell lines","volume":"7","author":"Mazars","year":"1992","journal-title":"Oncogene"},{"key":"10.4065\/82.3.323_bib58","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1182\/blood.V81.1.128.128","article-title":"p53 gene mutations in multiple myeloma are associated with advanced forms of malignancy","volume":"81","author":"Neri","year":"1993","journal-title":"Blood"},{"key":"10.4065\/82.3.323_bib59","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/j.1365-2141.1992.tb08253.x","article-title":"Rare occurrence of P53 gene mutations in multiple myeloma","volume":"81","author":"Preudhomme","year":"1992","journal-title":"Br J Haematol"},{"key":"10.4065\/82.3.323_bib60","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.V72.1.219.219","article-title":"Value of \u03b22 \u2014 microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myeloma","volume":"72","author":"Greipp","year":"1988","journal-title":"Blood"},{"key":"10.4065\/82.3.323_bib61","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1182\/blood.V81.12.3382.3382","article-title":"Plasma cell labeling index and \u03b22-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma","volume":"81","author":"Greipp","year":"1993","journal-title":"Blood"},{"key":"10.4065\/82.3.323_bib62","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.4065\/80.10.1371","article-title":"Multiple myeloma: diagnosis and treatment","volume":"80","author":"Rajkumar","year":"2005","journal-title":"Mayo Clin Proc"},{"key":"10.4065\/82.3.323_bib63","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.4065\/81.8.1047","article-title":"Mayo Clinic consensus statement for the use of bisphosphonates in multiple myeloma","volume":"81","author":"Lacy","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"10.4065\/82.3.323_bib64","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","article-title":"Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group","volume":"121","author":"International Myeloma Working Group","year":"2003","journal-title":"Br J Haematol"},{"key":"10.4065\/82.3.323_bib65","doi-asserted-by":"crossref","first-page":"949a","DOI":"10.1182\/blood.V106.11.3396.3396","article-title":"The natural history of smoldering (asymptomatic) multiple myeloma [abstract]","volume":"106","author":"Kyle","year":"2005","journal-title":"Blood"},{"key":"10.4065\/82.3.323_bib66","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1038\/bjc.1994.474","article-title":"Treatment of multiple myeloma according to the extension of the disease: a prospective, randomised study comparing a less with a more aggressive cystostatic policy","volume":"70","author":"Riccardi","year":"1994","journal-title":"Br J Cancer"},{"key":"10.4065\/82.3.323_bib67","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1054\/bjoc.1999.1087","article-title":"Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study","volume":"82","author":"Riccardi","year":"2000","journal-title":"Br J Cancer"},{"key":"10.4065\/82.3.323_bib68","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1600-0609.1993.tb00148.x","article-title":"Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I: a randomized study","volume":"50","author":"Hjorth","year":"1993","journal-title":"Eur J Haematol"},{"key":"10.4065\/82.3.323_bib69","doi-asserted-by":"crossref","first-page":"693","DOI":"10.4065\/81.5.693","article-title":"Monoclonal gammopathy of undetermined significance, Waldenstr\u00f6m macroglobulinemia, AL amyloidosis, and related plasma cell disorders: diagnosis and treatment","volume":"81","author":"Rajkumar","year":"2006","journal-title":"Mayo Clin Proc"},{"issue":"suppl","key":"10.4065\/82.3.323_bib70","first-page":"S31","article-title":"Risk factors for early progression of asymptomatic multiple myeloma [abstract]","volume":"4","author":"Weber","year":"2003","journal-title":"Hematol J"},{"key":"10.4065\/82.3.323_bib71","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1200\/JCO.20.6.1625","article-title":"Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma","volume":"20","author":"Cesana","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.4065\/82.3.323_bib72","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/j.1365-2141.1994.tb04908.x","article-title":"Detection of peripheral blood plasma cells as a predictor of disease course in patients with smouldering multiple myeloma","volume":"87","author":"Witzig","year":"1994","journal-title":"Br J Haematol"},{"key":"10.4065\/82.3.323_bib73","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1089\/jir.2006.26.83","article-title":"Identification of two groups of smoldering multiple myeloma patients who are either high or low producers of interleukin-1","volume":"26","author":"Xiong","year":"2006","journal-title":"J Interferon Cytokine Res"},{"key":"10.4065\/82.3.323_bib74","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1001\/archinte.1975.00330010159020","article-title":"Treatment of myeloma: comparison of melphalan, chlorambucil, and azathioprine","volume":"135","year":"1975","journal-title":"Arch Intern Med"},{"issue":"suppl","key":"10.4065\/82.3.323_bib75","doi-asserted-by":"crossref","first-page":"1s","DOI":"10.1200\/jco.2006.24.18_suppl.1","article-title":"Superiority of melphalan-prednisone (MP) + thalidomide (THAL) over MP and autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma [abstract]","volume":"24","author":"Facon","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.4065\/82.3.323_bib76","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1200\/JCO.1998.16.12.3832","article-title":"Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials","volume":"16","author":"Myeloma Trialists' Collaborative Group","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.4065\/82.3.323_bib77","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1182\/blood-2005-04-1588","article-title":"Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy","volume":"107","author":"Facon","year":"2006","journal-title":"Blood"},{"key":"10.4065\/82.3.323_bib78","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(06)68338-4","article-title":"Oral melphalan and prednisone chemotherapy plusthalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial","volume":"367","author":"Palumbo","year":"2006","journal-title":"Lancet"},{"key":"10.4065\/82.3.323_bib79","doi-asserted-by":"crossref","first-page":"230a","DOI":"10.1182\/blood.V106.11.780.780","article-title":"Major superiority of melphalan-prednisone (MP) + thalidomide (THAL) over MP and autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma [abstract]","volume":"106","author":"Facon","year":"2005","journal-title":"Blood"},{"key":"10.4065\/82.3.323_bib80","doi-asserted-by":"crossref","first-page":"231a","DOI":"10.1182\/blood.V106.11.782.782","article-title":"Thalidomide-dexamethasone versus melphalan-prednisolone as first line treatment in elderly patients with multiple myeloma: an interim analysis [abstract]","volume":"106","author":"Ludwig","year":"2005","journal-title":"Blood"},{"issue":"suppl","key":"10.4065\/82.3.323_bib81","first-page":"426s","article-title":"A multicenter, randomized, double-blind, placebo-controlled trial of thalidomide plus dexamethasone versus dexamethasone alone as initial therapy for newly diagnosed multiple myeloma [abstract]","volume":"24","author":"Rajkumar","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.4065\/82.3.323_bib82","first-page":"252","article-title":"Primary treatment with pulsed melphalan, dexamethasone and thalidomide for elderly symptomatic patients with multiple myeloma","volume":"91","author":"Dimopoulos","year":"2006","journal-title":"Haematologica"},{"key":"10.4065\/82.3.323_bib83","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1182\/blood-2006-03-013086","article-title":"Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma","volume":"108","author":"Offidani","year":"2006","journal-title":"Blood"},{"key":"10.4065\/82.3.323_bib84","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1182\/blood-2006-04-019778","article-title":"Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1\/2 study","volume":"108","author":"Mateos","year":"2006","journal-title":"Blood"},{"key":"10.4065\/82.3.323_bib85","doi-asserted-by":"crossref","first-page":"889","DOI":"10.4065\/81.7.889","article-title":"Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myeloma","volume":"81","author":"Hussein","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"10.4065\/82.3.323_bib86","doi-asserted-by":"crossref","first-page":"379b","DOI":"10.1182\/blood.V106.11.5180.5180","article-title":"Treatment of newly diagnosed, inner-city multiple myeloma patients with low-dose thalidomide in combination with dexamethasone and zoledronate: a phase II trial [abstract]","volume":"106","author":"Klueppelberg","year":"2005","journal-title":"Blood"},{"issue":"suppl","key":"10.4065\/82.3.323_bib87","first-page":"426s","article-title":"Oral lenalidomide plus melphalan and prednisone (R-MP) for newly diagnosed multiple myeloma [abstract]","volume":"24","author":"Palumbo","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.4065\/82.3.323_bib88","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1200\/JCO.2005.03.0221","article-title":"Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group","volume":"24","author":"Rajkumar","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.4065\/82.3.323_bib89","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1002\/cncr.21662","article-title":"Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a phase III multicenter randomized trial","volume":"106","author":"Rifkin","year":"2006","journal-title":"Cancer"},{"key":"10.4065\/82.3.323_bib90","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1093\/annonc\/mdg287","article-title":"Prospective randomized comparison of vincristine, doxorubicin and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal doxorubicin as first-line treatment in multiple myeloma","volume":"14","author":"Dimopoulos","year":"2003","journal-title":"Ann Oncol"},{"key":"10.4065\/82.3.323_bib91","doi-asserted-by":"crossref","first-page":"128a","DOI":"10.1182\/blood.V106.11.424.424","article-title":"HOVON 50\/GMMG-HD3-Trial: phase III study on the effect of thalidomide combined with high dose melphalan in myeloma patients up to 65 years [abstract]","volume":"106","author":"Goldschmidt","year":"2005","journal-title":"Blood"},{"key":"10.4065\/82.3.323_bib92","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1056\/NEJMoa053583","article-title":"Thalidomide and hematopoieticcell transplantation for multiple myeloma","volume":"354","author":"Barlogie","year":"2006","journal-title":"N Engl J Med"},{"key":"10.4065\/82.3.323_bib93","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1038\/sj.leu.2402183","article-title":"Thalidomide for previously untreated indolent or smoldering multiple myeloma","volume":"15","author":"Rajkumar","year":"2001","journal-title":"Leukemia"},{"key":"10.4065\/82.3.323_bib94","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/sj.leu.2402866","article-title":"Thalidomide as initial therapy for early-stage myeloma","volume":"17","author":"Rajkumar","year":"2003","journal-title":"Leukemia"},{"key":"10.4065\/82.3.323_bib95","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1200\/JCO.2003.03.139","article-title":"Thalidomide alone or with dexamethasone for previously untreated multiple myeloma","volume":"21","author":"Weber","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.4065\/82.3.323_bib96","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1200\/JCO.2002.02.116","article-title":"Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma","volume":"20","author":"Rajkumar","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.4065\/82.3.323_bib97","first-page":"862","article-title":"Combination chemotherapy with cyclophosphamide, thalidomide and dexamethasone for patients with refractory, newly diagnosed or relapsed myeloma","volume":"91","author":"Sidra","year":"2006","journal-title":"Haematologica"},{"key":"10.4065\/82.3.323_bib98","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1182\/blood-2005-07-2817","article-title":"Combination therapy with lenalidomide plus dexamethasone (Rev\/Dex) for newly diagnosed myeloma","volume":"106","author":"Rajkumar","year":"2005","journal-title":"Blood"},{"issue":"suppl","key":"10.4065\/82.3.323_bib99","first-page":"433s","article-title":"Clarithromycin, lenalidomide and dexamethasone combination therapy as primary treatment of multiple myeloma [abstract]","volume":"24","author":"Niesvizky","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.4065\/82.3.323_bib100","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/j.1365-2141.2005.05540.x","article-title":"Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma","volume":"129","author":"Jagannath","year":"2005","journal-title":"Br J Haematol"},{"key":"10.4065\/82.3.323_bib101","doi-asserted-by":"crossref","first-page":"231a","DOI":"10.1182\/blood.V106.11.783.783","article-title":"Bortezomib therapy alone and in combination and dexamathasone for patients with previously untreated multiple myeloma [abstract]","volume":"106","author":"Jagannath","year":"2005","journal-title":"Blood"},{"issue":"suppl","key":"10.4065\/82.3.323_bib102","first-page":"423s","article-title":"Single-agent bortezomib in previously untreated multiple myeloma (MM): results of a phase II multicenter study [abstract]","volume":"24","author":"Anderson","year":"2006","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"10.4065\/82.3.323_bib103","first-page":"598s","article-title":"Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: preliminary results of an IFM phase II study [abstract]","volume":"23","author":"Harousseau","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.4065\/82.3.323_bib104","first-page":"231a","article-title":"Rapid control of previously untreated multiple myeloma with bortezomib-thalidomide-dexamethasone followed by early intensive therapy [abstract]","volume":"106","author":"Wang","year":"2005","journal-title":"Blood"},{"key":"10.4065\/82.3.323_bib105","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1002\/cncr.10946","article-title":"A phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients","volume":"95","author":"Hussein","year":"2002","journal-title":"Cancer"},{"key":"10.4065\/82.3.323_bib106","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1365-2141.2005.05848.x","article-title":"Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma","volume":"132","author":"Hassoun","year":"2006","journal-title":"Br J Haematol"},{"key":"10.4065\/82.3.323_bib107","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1093\/annonc\/mdh026","article-title":"Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study","volume":"15","author":"Zervas","year":"2004","journal-title":"Ann Oncol"},{"key":"10.4065\/82.3.323_bib108","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/j.1365-2141.2005.05519.x","article-title":"PAD combination therapy (PS-341\/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma","volume":"129","author":"Oakervee","year":"2005","journal-title":"Br J Haematol"},{"key":"10.4065\/82.3.323_bib109","doi-asserted-by":"crossref","first-page":"717a","DOI":"10.1182\/blood.V106.11.2554.2554","article-title":"Reduced dose PAD combination therapy (PS-341\/bortezomib, adriamycin and dexamethasone) for previously untreated patients with multiple myeloma [abstract]","volume":"106","author":"Popat","year":"2005","journal-title":"Blood"},{"key":"10.4065\/82.3.323_bib110","doi-asserted-by":"crossref","first-page":"771a","DOI":"10.1182\/blood.V106.11.2747.2747","article-title":"Phase I trial of bortezomib (V) in combination with \u201cDT-PACE\u201d: toxicity, stem cell collection and engraftment in newly diagnosed multiple myeloma (MM) patients (Pts) [abstract]","volume":"106","author":"Badros","year":"2005","journal-title":"Blood"},{"key":"10.4065\/82.3.323_bib111","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1182\/blood-2005-10-4084","article-title":"Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies","volume":"107","author":"Barlogie","year":"2006","journal-title":"Blood"},{"key":"10.4065\/82.3.323_bib112","article-title":"Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed\/refractory multiple myeloma","author":"Chang","year":"2006","journal-title":"Leuk Res"},{"key":"10.4065\/82.3.323_bib113","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/sj.leu.2404442","article-title":"Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials","volume":"21","author":"Jagannath","year":"2007","journal-title":"Leukemia"},{"key":"10.4065\/82.3.323_bib114","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/sj.leu.2404459","article-title":"Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion","volume":"21","author":"Sagaster","year":"2007","journal-title":"Leukemia"},{"key":"10.4065\/82.3.323_bib115","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1182\/blood-2005-09-3869","article-title":"Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma","volume":"107","author":"Garban","year":"2006","journal-title":"Blood"},{"key":"10.4065\/82.3.323_bib116","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1182\/blood-2005-06-2573","article-title":"Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol","volume":"107","author":"Moreau","year":"2006","journal-title":"Blood"},{"key":"10.4065\/82.3.323_bib117","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1056\/NEJM197011192832101","article-title":"Multiple myeloma and acute myelomonocytic leukemia","volume":"283","author":"Kyle","year":"1970","journal-title":"N Engl J Med"},{"key":"10.4065\/82.3.323_bib118","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/j.0954-6820.1966.tb02358.x","article-title":"Myelomatosis: a clinical review of 310 cases","volume":"445","author":"Nordenson","year":"1966","journal-title":"Acta Med Scand Suppl"},{"key":"10.4065\/82.3.323_bib119","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/0002-9343(67)90164-7","article-title":"Extraosseous lesions in plasma cell myeloma: a report of six cases","volume":"43","author":"Edwards","year":"1967","journal-title":"Am J Med"},{"key":"10.4065\/82.3.323_bib120","doi-asserted-by":"crossref","first-page":"440","DOI":"10.7326\/0003-4819-86-4-440","article-title":"Acute leukemia in multiple myeloma","volume":"86","author":"Gonzalez","year":"1977","journal-title":"Ann Intern Med"},{"key":"10.4065\/82.3.323_bib121","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1056\/NEJM197910043011402","article-title":"The chemotherapy on plasma-cell myeloma and the incidence of acute leukemia","volume":"301","author":"Bergsagel","year":"1979","journal-title":"N Engl J Med"},{"key":"10.4065\/82.3.323_bib122","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/hon.2900060215","article-title":"Results of the MRC myelomatosis trials for patients entered since 1980","volume":"6","author":"MacLennan","year":"1988","journal-title":"Hematol Oncol"},{"key":"10.4065\/82.3.323_bib123","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/bjc.1985.171","article-title":"Objective evaluation of the role of vincristine in induction and maintenance therapy for myelomatosis","volume":"52","author":"MacLennan","year":"1985","journal-title":"Br J Cancer"},{"key":"10.4065\/82.3.323_bib124","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1001\/archinte.1975.00330010149019","article-title":"Remission maintenance therapy for multiple myeloma","volume":"135","year":"1975","journal-title":"Arch Intern Med"},{"key":"10.4065\/82.3.323_bib125","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1200\/JCO.1986.4.6.888","article-title":"Consolidation and maintenance therapy in multiple myeloma: randomized comparison of a new approach to therapy after initial response to treatment","volume":"4","author":"Cohen","year":"1986","journal-title":"J Clin Oncol"},{"key":"10.4065\/82.3.323_bib126","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/0277-5379(88)90160-5","article-title":"Induction and maintenance therapy in multiple myeloma: a multicenter trial of MP versus VCMP","volume":"24","author":"Peest","year":"1988","journal-title":"Eur J Cancer Clin Oncol"},{"key":"10.4065\/82.3.323_bib127","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/bjc.1988.17","article-title":"A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients","volume":"57","author":"Belch","year":"1988","journal-title":"Br J Cancer"},{"key":"10.4065\/82.3.323_bib128","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1600-0609.1988.tb00867.x","article-title":"Multiple myeloma in central and northern Norway 1981-1982: a follow-up study of a randomized clinical trial of 5-drug combination therapy versus standard therapy","volume":"41","author":"Kildahl-Andersen","year":"1988","journal-title":"Eur J Haematol"},{"key":"10.4065\/82.3.323_bib129","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/bjc.1980.329","article-title":"Treatment comparisons in the third MRC myelomatosis trial","volume":"42","author":"Medical Research Council's Working Party on Leukaemia in Adults","year":"1980","journal-title":"Br J Cancer"},{"key":"10.4065\/82.3.323_bib130","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1182\/blood.V51.6.1005.1005","article-title":"Unmaintained remissions in multiple myeloma","volume":"51","author":"Alexanian","year":"1978","journal-title":"Blood"},{"key":"10.4065\/82.3.323_bib131","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1182\/blood.V99.9.3163","article-title":"Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients","volume":"99","author":"Berenson","year":"2002","journal-title":"Blood"},{"key":"10.4065\/82.3.323_bib132","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/1096-8652(200011)65:3<204::AID-AJH5>3.0.CO;2-H","article-title":"Randomized trial of \u03b1-interferon or dexamethasone as maintenance treatment for multiple myeloma","volume":"65","author":"Alexanian","year":"2000","journal-title":"Am J Hematol"},{"key":"10.4065\/82.3.323_bib133","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJM199005173222005","article-title":"Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy","volume":"322","author":"Mandelli","year":"1990","journal-title":"N Engl J Med"},{"key":"10.4065\/82.3.323_bib134","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1080\/028418600750063569","article-title":"Interferon in multiple myeloma: summary of treatment results and clinical implications","volume":"39","author":"Ludwig","year":"2000","journal-title":"Acta Oncol"},{"key":"10.4065\/82.3.323_bib135","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1046\/j.1365-2141.2001.02857.x","article-title":"Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients","volume":"113","author":"Myeloma Trialists' Collaborative Group","year":"2001","journal-title":"Br J Haematol"},{"key":"10.4065\/82.3.323_bib136","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/j.1600-0609.1985.tb02826.x","article-title":"Correlation between in vitro and in vivo sensitivity to human leucocyte interferon in patients with multiple myeloma","volume":"35","author":"Brenning","year":"1985","journal-title":"Scand J Haematol"},{"key":"10.4065\/82.3.323_bib137","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1182\/blood-2005-04-1411","article-title":"Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy","volume":"106","author":"Gertz","year":"2005","journal-title":"Blood"},{"key":"10.4065\/82.3.323_bib138","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1365-2141.2004.04867.x","article-title":"The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant","volume":"125","author":"Chang","year":"2004","journal-title":"Br J Haematol"},{"key":"10.4065\/82.3.323_bib139","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1182\/blood-2004-04-1363","article-title":"p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation","volume":"105","author":"Chang","year":"2005","journal-title":"Blood"},{"key":"10.4065\/82.3.323_bib140","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1182\/blood-2006-05-022962","article-title":"Maintenance therapy with thalidomide improves survival in patients with multiple myeloma","volume":"108","author":"Attal","year":"2006","journal-title":"Blood"},{"key":"10.4065\/82.3.323_bib141","doi-asserted-by":"crossref","first-page":"8170","DOI":"10.1158\/1078-0432.CCR-04-1106","article-title":"Results of a multicenter randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma after autologous stem cell transplant","volume":"10","author":"Stewart","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.4065\/82.3.323_bib142","doi-asserted-by":"crossref","first-page":"239a","DOI":"10.1182\/blood.V108.11.799.799","article-title":"A randomized phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group [abstract]","volume":"108","author":"Rajkumar","year":"2006","journal-title":"Blood"},{"key":"10.4065\/82.3.323_bib143","first-page":"1498","article-title":"Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study","volume":"91","author":"Harousseau","year":"2006","journal-title":"Haematologica"},{"key":"10.4065\/82.3.323_bib144","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJM198405243102104","article-title":"Effective treatment of advanced multiple myeloma refractory to alkylating agents","volume":"310","author":"Barlogie","year":"1984","journal-title":"N Engl J Med"},{"key":"10.4065\/82.3.323_bib145","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/bjc.1988.243","article-title":"Infused vincristine and adriamycin with high dose methylprednisolone (VAMP) in advanced previously treated multiple myeloma patients","volume":"58","author":"Forgeson","year":"1988","journal-title":"Br J Cancer"},{"key":"10.4065\/82.3.323_bib146","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/ajh.2830330203","article-title":"VAD-based regimens as primary treatment for multiple myeloma","volume":"33","author":"Alexanian","year":"1990","journal-title":"Am J Hematol"},{"key":"10.4065\/82.3.323_bib147","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/S0140-6736(89)91549-3","article-title":"Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma","volume":"2","author":"Samson","year":"1989","journal-title":"Lancet"},{"key":"10.4065\/82.3.323_bib148","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1182\/blood.V79.5.1130.1130","article-title":"Intensive combined therapy for previously untreated aggressive myeloma","volume":"79","author":"Attal","year":"1992","journal-title":"Blood"},{"key":"10.4065\/82.3.323_bib149","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1046\/j.1365-2141.1997.d01-2122.x","article-title":"A comparison of vincristine and doxorubicin infusional chemotherapy with methylprednisolone (VAMP) with the addition of weekly cyclophosphamide (C-VAMP) as induction treatment followed by autografting in previously untreated myeloma","volume":"97","author":"Raje","year":"1997","journal-title":"Br J Haematol"},{"key":"10.4065\/82.3.323_bib150","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/j.1600-0609.1997.tb00732.x","article-title":"Maintenance therapy with alpha-interferon following first-line VAD in multiple myeloma","volume":"59","author":"Kars","year":"1997","journal-title":"Eur J Haematol"},{"key":"10.4065\/82.3.323_bib151","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/bjc.1995.65","article-title":"VAD chemotherapy as remission induction for multiple myeloma","volume":"71","author":"Anderson","year":"1995","journal-title":"Br J Cancer"},{"key":"10.4065\/82.3.323_bib152","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1365-2141.1999.01279.x","article-title":"Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma","volume":"105","author":"Segeren","year":"1999","journal-title":"Br J Haematol"},{"key":"10.4065\/82.3.323_bib153","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/sj.leu.2400945","article-title":"Bolus vincristine and epirubicin with cyclophosphamide and dexamethasone (VECD) as induction and salvage treatment in multiple myeloma","volume":"12","author":"Fossa","year":"1998","journal-title":"Leukemia"},{"key":"10.4065\/82.3.323_bib154","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1034\/j.1600-0609.2000.90145.x","article-title":"Administration of a modified chemotherapeutic regimen containing vincristine, liposomal doxorubicin and dexamethasone to multiple myeloma patients: preliminary data","volume":"65","author":"Tsiara","year":"2000","journal-title":"Eur J Haematol"},{"key":"10.4065\/82.3.323_bib155","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1200\/JCO.1998.16.3.890","article-title":"Interferon versus interferon plus prednisone remission maintenance therapy for multiple myeloma: a Southwest Oncology Group Study","volume":"16","author":"Salmon","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.4065\/82.3.323_bib156","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1182\/blood.V80.4.887.887","article-title":"Primary dexamethasone treatment of multiple myeloma","volume":"80","author":"Alexanian","year":"1992","journal-title":"Blood"},{"key":"10.4065\/82.3.323_bib157","first-page":"683a","article-title":"Autologous stem cell transplantation (ASCT) after nonmyelosuppressive induction therapy with dexamethasone alone is safe and effective for newly diagnosed multiple myeloma (MM) pts who receive high dose chemotherapy (HDC)","volume":"98","author":"Anagnostopoulos","year":"2001","journal-title":"Blood"},{"key":"10.4065\/82.3.323_bib158","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/sj.bmt.1704633","article-title":"Single agent dexamethasone for pre-stem cell transplant induction therapy for multiple myeloma","volume":"34","author":"Kumar","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.4065\/82.3.323_bib159","doi-asserted-by":"crossref","first-page":"1006a","DOI":"10.1182\/blood.V108.11.3527.3527","article-title":"Single agent bortezomib is associated with a high response rate in patients with high risk myeloma: a phase II study from the Eastern Cooperative Oncology Group (E2A02) [abstract]","volume":"108","author":"Dispenzieri","year":"2006","journal-title":"Blood"},{"key":"10.4065\/82.3.323_bib160","doi-asserted-by":"crossref","first-page":"239a","DOI":"10.1182\/blood.V108.11.798.798","article-title":"Lenalidomide plus dexamethasone (rev\/dex) in newly diagnosed myeloma: response to therapy, time to progression, and survival [abstract]","volume":"108","author":"Lacy","year":"2006","journal-title":"Blood"},{"key":"10.4065\/82.3.323_bib161","doi-asserted-by":"crossref","first-page":"6a","DOI":"10.1182\/blood.V106.11.6.6","article-title":"Study of lenalidomide plus dexamethasone versus dexamethasone alone in relapsed or refractory multiple myeloma (MM): results of a phase 3 study (MM-010) [abstract]","volume":"106","author":"Dimopoulos","year":"2005","journal-title":"Blood"},{"issue":"suppl","key":"10.4065\/82.3.323_bib162","first-page":"427s","article-title":"Lenalidomide plus high-dose dexamethasone provides improved overall survival compared to high-dose dexamathasone alone for relapsed or refractory multiple myeloma (MM): results of a North American phase III study (MM-009) [abstract]","volume":"24","author":"Weber","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.4065\/82.3.323_bib163","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1056\/NEJMc053530","article-title":"Lenalidomide and venous thrombosis in multiple myeloma","volume":"354","author":"Rajkumar","year":"2006","journal-title":"N Engl J Med"},{"key":"10.4065\/82.3.323_bib164","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/sj.bmt.1701559","article-title":"Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma","volume":"23","author":"Gertz","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"10.4065\/82.3.323_bib165","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1182\/blood.V85.2.588.588","article-title":"Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients","volume":"85","author":"Tricot","year":"1995","journal-title":"Blood"},{"key":"10.4065\/82.3.323_bib166","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1046\/j.1365-2141.1997.2783095.x","article-title":"Factors influencing collection of peripheral blood progenitor cells following high-dose cyclophosphamide and granulocyte colony-stimulating factor in patients with multiple myeloma","volume":"98","author":"Goldschmidt","year":"1997","journal-title":"Br J Haematol"},{"key":"10.4065\/82.3.323_bib167","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s002770050398","article-title":"Successful mobilization of peripheral blood stem cells in heavily pretreated myeloma patients with G-CSF alone","volume":"76","author":"Kroger","year":"1998","journal-title":"Ann Hematol"},{"key":"10.4065\/82.3.323_bib168","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","article-title":"A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma","volume":"335","author":"Attal","year":"1996","journal-title":"N Engl J Med"},{"key":"10.4065\/82.3.323_bib169","first-page":"7","article-title":"Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study","volume":"95","author":"Lenhoff","year":"2000","journal-title":"Blood"},{"key":"10.4065\/82.3.323_bib170","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMoa022340","article-title":"High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma","volume":"348","author":"Child","year":"2003","journal-title":"N Engl J Med"},{"key":"10.4065\/82.3.323_bib171","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1182\/blood-2004-02-0408","article-title":"Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial","volume":"104","author":"Palumbo","year":"2004","journal-title":"Blood"},{"key":"10.4065\/82.3.323_bib172","doi-asserted-by":"crossref","first-page":"9227","DOI":"10.1200\/JCO.2005.03.0551","article-title":"High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe","volume":"23","author":"Fermand","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.4065\/82.3.323_bib173","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1182\/blood.V92.9.3131","article-title":"High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: upfront or rescue treatment? results of a multicenter sequential randomized clinical trial","volume":"92","author":"Fermand","year":"1998","journal-title":"Blood"},{"key":"10.4065\/82.3.323_bib174","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1200\/JCO.2005.04.5807","article-title":"Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321 [published correction appears in J Clin Oncol. 2006;24:2687]","volume":"24","author":"Barlogie","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.4065\/82.3.323_bib175","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1182\/blood-2005-03-1301","article-title":"High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA","volume":"106","author":"Blade","year":"2005","journal-title":"Blood"},{"key":"10.4065\/82.3.323_bib176","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0268-960X(02)00043-7","article-title":"The role of stem cell transplantation in multiple myeloma","volume":"16","author":"Harousseau","year":"2002","journal-title":"Blood Rev"},{"key":"10.4065\/82.3.323_bib177","doi-asserted-by":"crossref","first-page":"715a","DOI":"10.1182\/blood.V106.11.2545.2545","article-title":"Intensive versus double intensive therapy in untreated multiple myeloma: final analysis of the HOVON 24 trial [abstract]","volume":"106","author":"Sonneveld","year":"2005","journal-title":"Blood"},{"key":"10.4065\/82.3.323_bib178","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa032290","article-title":"Single versus double autologous stem-cell transplantation for multiple myeloma [published correction appears in N Engl J Med. 2004;350: 2628]","volume":"349","author":"Attal","year":"2003","journal-title":"N Engl J Med"},{"key":"10.4065\/82.3.323_bib179","first-page":"155a","article-title":"Superiority of double over single autologous stem cell transplantation as first-line therapy for multiple myeloma [abstract]","volume":"104","author":"Cavo","year":"2004","journal-title":"Blood"},{"key":"10.4065\/82.3.323_bib180","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.beha.2005.01.005","article-title":"Stem-cell transplantation in multiple myeloma","volume":"18","author":"Harousseau","year":"2005","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.4065\/82.3.323_bib181","first-page":"815a","volume":"98","author":"Fermand","year":"2001","journal-title":"Blood"},{"key":"10.4065\/82.3.323_bib182","doi-asserted-by":"crossref","first-page":"413a","DOI":"10.1182\/blood.V104.11.1480.1480","article-title":"Marked activity of velcade plus thalidomide (V+T) in advanced and refractory multiple myeloma (MM) [abstract]","volume":"104","author":"Zangari","year":"2004","journal-title":"Blood"},{"issue":"suppl","key":"10.4065\/82.3.323_bib183","first-page":"683s","article-title":"Addition of bortezomib to thalidomide, dexamethasone and zoledronic acid (VTD-Z regimen) significantly improves complete remission rates in patients with relapsed\/refractory multiple myeloma [abstract]","volume":"24","author":"Teoh","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.4065\/82.3.323_bib184","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1200\/JCO.2000.18.11.2273","article-title":"Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma","volume":"18","author":"Martinelli","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.4065\/82.3.323_bib185","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1182\/blood-2003-01-0189","article-title":"Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma","volume":"102","author":"Corradini","year":"2003","journal-title":"Blood"},{"key":"10.4065\/82.3.323_bib186","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1182\/blood.V88.7.2787.bloodjournal8872787","article-title":"Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome","volume":"88","author":"Bensinger","year":"1996","journal-title":"Blood"},{"key":"10.4065\/82.3.323_bib187","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/sj.bmt.1701280","article-title":"High-dose busulfan and cyclophosphamide are an effective conditioning regimen for allogeneic bone marrow transplantation in chemosensitive multiple myeloma","volume":"22","author":"Cavo","year":"1998","journal-title":"Bone Marrow Transplant"},{"key":"10.4065\/82.3.323_bib188","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1056\/NEJM199110313251802","article-title":"Allogeneic bone marrow transplantation in multiple myeloma","volume":"325","author":"Gahrton","year":"1991","journal-title":"N Engl J Med"},{"issue":"suppl","key":"10.4065\/82.3.323_bib189","first-page":"122","article-title":"An update of prognostic factors for allogeneic bone marrow transplantation in multiple myeloma using matched sibling donors","volume":"13","author":"Gahrton","year":"1995","journal-title":"Stem Cells"},{"key":"10.4065\/82.3.323_bib190","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1365-2257.2006.00773.x","article-title":"Myeloablative allogeneic stem cell transplantation for advanced stage multiple myeloma: very long-term follow up of a single center experience","volume":"28","author":"Kennedy","year":"2006","journal-title":"Clin Lab Haematol"},{"key":"10.4065\/82.3.323_bib191","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2004-06-2387","article-title":"Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT","volume":"105","author":"Crawley","year":"2005","journal-title":"Blood"},{"key":"10.4065\/82.3.323_bib192","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1182\/blood-2002-09-2955","article-title":"Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma","volume":"102","author":"Maloney","year":"2003","journal-title":"Blood"},{"key":"10.4065\/82.3.323_bib193","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1182\/blood-2002-01-0131","article-title":"Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma","volume":"100","author":"Kroger","year":"2002","journal-title":"Blood"},{"key":"10.4065\/82.3.323_bib194","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1080\/10428190500080850","article-title":"Autologous-allogeneic tandem stem cell transplantation in patients with multiple myeloma","volume":"46","author":"Kroger","year":"2005","journal-title":"Leuk Lymphoma"},{"key":"10.4065\/82.3.323_bib195","doi-asserted-by":"crossref","first-page":"3919","DOI":"10.1182\/blood-2002-04-1150","article-title":"Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality","volume":"100","author":"Kroger","year":"2002","journal-title":"Blood"},{"key":"10.4065\/82.3.323_bib196","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/sj.bmt.1705131","article-title":"Genetic risk identifies multiple myeloma patients who do not benefit from autologous stem cell transplantation","volume":"36","author":"Chang","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.4065\/82.3.323_bib197","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1182\/blood.V93.1.51","article-title":"Age is not a prognostic variable with autotransplants for multiple myeloma","volume":"93","author":"Siegel","year":"1999","journal-title":"Blood"},{"key":"10.4065\/82.3.323_bib198","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1182\/blood.V97.9.2574","article-title":"High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions [published corrections appear in Blood. 2001;98:271 and 1653]","volume":"97","author":"Badros","year":"2001","journal-title":"Blood"},{"key":"10.4065\/82.3.323_bib199","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/sj.thj.6200003","article-title":"Are myeloma patients with renal failure candidates for autologous stem cell transplantation?","volume":"1","author":"San Miguel","year":"2000","journal-title":"Hematol J"},{"key":"10.4065\/82.3.323_bib200","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/sj.bmt.1704440","article-title":"Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant","volume":"33","author":"Lee","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.4065\/82.3.323_bib201","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1600-0609.2005.00446.x","article-title":"Autologous stem cell transplantation in multiple myeloma: outcome in patients with renal failure","volume":"75","author":"Knudsen","year":"2005","journal-title":"Eur J Haematol"},{"key":"10.4065\/82.3.323_bib202","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1046\/j.1365-2141.1998.00795.x","article-title":"A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: long-term follow-up results","volume":"102","author":"Cunningham","year":"1998","journal-title":"Br J Haematol"},{"key":"10.4065\/82.3.323_bib203","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/sj.bmt.1702826","volume":"27","author":"Bjorkstrand","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.4065\/82.3.323_bib204","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1002\/cncr.21852","article-title":"Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma","volume":"106","author":"Brinker","year":"2006","journal-title":"Cancer"},{"key":"10.4065\/82.3.323_bib205","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/j.1365-2141.2004.05078.x","article-title":"Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation","volume":"126","author":"Zangari","year":"2004","journal-title":"Br J Haematol"},{"key":"10.4065\/82.3.323_bib206","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.4065\/80.12.1568","article-title":"The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma","volume":"80","author":"Baz","year":"2005","journal-title":"Mayo Clin Proc"},{"key":"10.4065\/82.3.323_bib207","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1056\/NEJMc053530","article-title":"Lenalidomide and venous thrombosis in multiple myeloma","volume":"354","author":"Knight","year":"2006","journal-title":"N Engl J Med"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002561961161029X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002561961161029X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,3,9]],"date-time":"2024-03-09T12:26:54Z","timestamp":1709987214000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002561961161029X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3]]},"references-count":207,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,3]]}},"alternative-id":["S002561961161029X"],"URL":"https:\/\/doi.org\/10.4065\/82.3.323","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2007,3]]}}}